PFE Stock Price Today (September 2026) — Pfizer Inc. Analysis & Key Metrics 2026-09-03
Pfizer Inc. (PFE) is trading at $28.81, down 0.72% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $28.61 (-0.7% upside).
- Volatility remains elevated (19.52% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.60% YoY) alongside significant competitive pressures.
PFE Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Pfizer Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $211.44B
P/E Ratio
Forward P/E: 9.83
Revenue Growth
Year over Year
Analyst Target
+-0.7% upside potential
Key Investor Questions About PFE
What investors need to know before buying
Based on current market data, PFE presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 69.72)
- Fundamentals say: Caution warranted (high leverage concerns)
PFE's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PFE investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $63.48B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, PFE stock traded between $23.58 and $28.75—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.52% annualized volatility and β=0.46, the stock exhibits low sensitivity to market moves—making PFE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value
Pfizer stock has quietly put up a 25.6% gain over the past year, yet broad valuation checks still do not flag it as either clearly cheap or clearly expensive. With mixed signals on value and fresh product news in the background, investors are weighing how much of the recent optimism is already reflected in the share price. The 25.6% 1 year return suggests sentiment toward Pfizer has improved meaningfully, which raises the bar for further upside driven purely by valuation. Approval of Pfizer...
Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check
Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...
3 Things You Need to Know If You Buy Pfizer Stock Today
After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime soon?
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.
Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today?
Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage.
Explore More Analysis for PFE
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Pfizer Inc.
Pfizer Inc. (PFE) is currently trading at $28.81. The RSI (14-day) is at 69.7, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $28.61 implies 0.7% downside from current levels. Volatility is low at 19.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Pfizer Inc. (PFE): The trailing P/E ratio is 37.42, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 9.83, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.71, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.93. Price-to-Sales is 2.58. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering PFE, the consensus price target is $28.61. This represents a 0.7% downside from the current price of $28.81. The range spans from a low target of $25.00 to a high target of $35.75, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Pfizer Inc. (PFE) pays a dividend with a current yield of approximately 5.97%. The annualized dividend rate is $1.72 per share. The payout ratio is 226.3%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-07-24T00:00:00.000Z.
Key risks for Pfizer Inc. (PFE) investors include: 1. Unsustainable dividend payout ratio (226%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Pfizer Inc.'s (PFE) current debt and financial health profile: Total debt stands at $63.48B. The debt-to-equity ratio is 74.25, which is moderate and generally manageable for most companies. The current ratio is 1.27, indicating adequate short-term liquidity. The quick ratio is 0.85. The company holds $11.70B in cash and equivalents. Free cash flow is positive at $12.49B, providing a cushion for debt servicing and shareholder returns.